#read

BioNTech steps in and takes over CureVac in billion-euro deal

The Mainz-based mRNA pioneer BioNTech wants to take over its Tübingen-based competitor CureVac and is paying for it with its own shares. The deal is more than just an acquisition: it is a strategic exclamation mark for the future of cancer medicine. BioNTech is specifically strengthening its oncology division through the takeover and is acquiring additional technologies and production capacities. In return, CureVac shareholders will receive BioNTech shares. The price is around 55 per cent above the average share price of recent months and values CureVac at around USD 1.25 billion.

12/06/2025

Both companies are united by the vision of a new generation of mRNA-based cancer therapies. BioNTech intends to seamlessly integrate the existing CureVac structures, including the site in Tübingen. Support is coming not only from CureVac's management, but also from long-standing majority shareholder Dietmar Hopp and the German government. With the shares already committed, BioNTech has a good chance of achieving the necessary majority for the exchange offer. This is a clear signal to the market that the use of mRNA has a promising future far beyond corona.

News from "BIONTECH" dated 12 June 2025

The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.

Click here to access the original content